Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
At a glance
Conditions
NCT07163273
Where you'd take part
This study runs at 7 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Imbert Cancer Center
Bay Shore, New Yorkstudy coordinator listed
Recruiting
Long Island Jewish Medical Center
New Hyde Park, New Yorkstudy coordinator listed
Recruiting
Manhattan Eye, Ear and Throat Hospital
New York, New Yorkstudy coordinator listed
Recruiting
NHPP Medical Oncology at Rego Park
Rego Park, New Yorkstudy coordinator listed
Recruiting
Northern Westchester Cancer Center
Mount Kisco, New Yorkstudy coordinator listed
Recruiting
Phelps Cancer Center
Sleepy Hollow, New Yorkstudy coordinator listed
Recruiting
Zuckerberg Cancer Center
New Hyde Park, New Yorkstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Determine 6-month Progression Free Survival (PFS)6 months
The primary endpoint is 6-month PFS rate defined as the proportion of patients alive and progression free (by RECIST v.1.1) at 6 months after treatment initiation. PFS events will be classified as either local progression, distant recurrence, secondary malignancy, or death.